Characterization of IDN-6556 (3-{2-(2-tert-Butyl-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5, 6-tetrafluoro-phenoxy)-pentanoic Acid): A Liver-Targeted Caspase Inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 2, 2004, Pages 634-640

  Hoglen, Niel C ^a   Chen, Long Shiuh ^a   Fisher, Craig D ^a   Hirakawa, Brad P ^a   Groessl, Todd ^a   Contreras, Patricia C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALANINE AMINOTRANSFERASE; CASPASE; CASPASE INHIBITOR; FAS ANTIBODY; GALACTOSAMINE; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG LIVER LEVEL; ENZYME ACTIVITY; FIRST PASS EFFECT; LIVER DISEASE; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CASPASES; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; PENTANOIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 2142810153     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.062034     Document Type: Article

References (22)

1. Bahrami S, Redl H, Leichtfried G, Yu Y, and Schlag G (1994) Similar cytokine but different coagulation responses to lipopolysaccharide injection in D-galactosamine-sensitized versus nonsensitized rats. Infect Immun 62:99-105.
2. Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326:1-16.
3. Earnshaw WC, Martins LM, and Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu Rev Biochem 68:383-424.
4. Galle PR (1997) Apoptosis in liver disease. J Hepatol 27:405-412.
5. Galle PR and Krammer PH (1998) CD95-induced apoptosis in human liver disease. Semin Liver Dis 18:141-151.
6. Gujral JS, Farhood A, and Jaeschke H (2003) Oncotic necrosis and caspase-dependent apoptosis during galactosamine-induced liver injury in rats. Toxicol Appl Pharmacol 190:37-46.
7. Hoglen NC, Hirakawa BP, Fisher CD, Weeks S, Srinivasan A, Wong AM, Valentino KL, Tomaselli KJ, Bai X, Karanewsky DS, et al. (2001) Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. J Pharmacol Exp Ther 297:811-818.
8. Jaeschke H, Fisher MA, Lawson JA, Simmons CA, Farhood A, and Jones DA (1998) Activation of caspase 3 (CPP32)-like proteases is essential for TNF-α-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J Immunol 160:3480-3486.
9. Kawahara H, Matsuda Y, and Takase S (1994) Is apoptosis involved in alcoholic hepatitis? Alcohol 29 (Suppl 1):113-118.
10. Kunstle G, Leist M, Uhlig S, Revesz L, Feifel R, MacKenzie A, and Wendel A (1997) ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-α. Immunol Lett 55:5-10.
11. Lau JY, Xie X, Lai MM, and Wu PC (1998) Apoptosis and viral hepatitis. Semin Liver Dis 18:169-176.
12. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, and Stieger B (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in the rat and human liver. Hepatology 26:1667-1677.
13. Mignon A, Rouquet N, Fabre M, Martin S, Pages JC, Dhainaut JF, Kahn A, Briand P, and Joulin V (1999) LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Am J Respir Crit Care Med 159:1308-1315.
14. Natori S, Higuchi H, Contreras P, and Gores GJ (2003) The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transplant 9:278-284.
15. Natori S, Selzner M, Valentino KL, Fritz LC, Srinivasan A, Clavien PA, and Gores GJ (1999) Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation 68:89-96.
16. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, and Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature (Lond) 384:806-809.
17. Rodriguez I, Matsuura K, Ody C, Nagata S, and Vassalli P (1996) Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against fas-mediated fulminant liver destruction and death. J Exp Med 184:2067-2072.
18. Stachlewitz RF, Seabra V, Bradford B, Bradham CA, Rusyn I, Germolec D, and Thurman RG (1999) Glycine and uridine prevent D-galactosamine hepatotoxicity in the rat: role of Kupffer cells. Hepatology 29:737-745.
19. Strand S, Hofmann WJ, Grambihler A, Hug H, Volkmann M, Otto G, Wesch H, Mariani SM, Hack V, Stremmel W, et al. (1998) Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 4:588-593.
20. Suzuki A (1998) The dominant role of CPP32 subfamily in Fas-mediated hepatitis. Proc Soc Exp Biol Med 27:450-454.
21. Tannapfel A, Kohlhaw K, Ebelt J, Hauss J, Liebert U, Berr F, and Wittekind C (1999) Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Transplantation 67:1079-1083.
22. Valentino KL, Gutierrez M, Sanchez R, Winship MJ, and Shapiro DA (2003) First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 41:441-449.